Vimarsana
Biggest News Aggregation in the World

Michael Rogawski News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Michael Rogawski. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Michael Rogawski Today - Breaking & Trending Today

New drug shows promise for epilepsy patients with resistant seizures - Vimarsana News

New drug shows promise for epilepsy patients with resistant seizures

In cases where standard therapies fail, a medication called XEN1101 reduces seizure frequency by more than 50% in some patients and sometimes eliminates them altogether, a new study shows.

New Investigational Drug Offers Relief for Treatment-Resistant Epilepsy Patients - Vimarsana News

New Investigational Drug Offers Relief for Treatment-Resistant Epilepsy Patients

NEW YORK, Oct. 9, 2023 /PRNewswire/ -- In cases where standard therapies fail, an investigational medication called XEN1101 reduces seizure freque...

CHANCELL-ING: Supporting Our Mental Health - Vimarsana News

CHANCELL-ING: Supporting Our Mental Health

May is Mental Health Awareness Month. So, I planned to begin this column with a nod to the many challenges we have faced in recent years, both as a community and as a nation, and the toll these challenges have taken on our collective mental health. That was before the past week’s horrific crimes, which have deeply impacted our entire community and shaken our sense of safety and well-being. 

Texas A&M Researcher Helps Develop First Treatment For Rare Type Of Refractory Epilepsy - Vimarsana News

Texas A&M Researcher Helps Develop First Treatment For Rare Type Of Refractory Epilepsy

Samba Reddy has spent decades working to bring ganaxolone and neurosteroid replacement therapy to patients.

Source: tamu.edu
Mindset Pharma Inc recaps 2021 milestones as it expands portfolio of next-generation psychedelic compounds - Vimarsana News

Mindset Pharma Inc recaps 2021 milestones as it expands portfolio of next-generation psychedelic compounds

As the company enters 2022, it is progressing with investigational new drug-enabling studies for its lead candidate MSP-1014